Compare ACR & MSLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ACR | MSLE |
|---|---|---|
| Founded | 2005 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 146.1M | 154.6M |
| IPO Year | 2005 | 2007 |
| Metric | ACR | MSLE |
|---|---|---|
| Price | $14.10 | $10.02 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $24.50 | N/A |
| AVG Volume (30 Days) | 27.6K | ★ 53.0K |
| Earning Date | 04-30-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $79,946,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $19.59 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $14.11 | $5.44 |
| 52 Week High | $24.61 | $13.39 |
| Indicator | ACR | MSLE |
|---|---|---|
| Relative Strength Index (RSI) | 29.72 | 64.20 |
| Support Level | N/A | $9.10 |
| Resistance Level | $18.56 | $10.70 |
| Average True Range (ATR) | 0.88 | 0.63 |
| MACD | -0.31 | -0.04 |
| Stochastic Oscillator | 6.36 | 57.50 |
ACRES Commercial Realty Corp is a commercial real estate investment trust that focuses on originating, holding, and managing commercial real estate (CRE) mortgage loans and equity investments in commercial real estate properties through direct ownership and joint ventures. The company invests in commercial real-estate-related assets, including whole loans, A notes, B notes, mezzanine loans, and mortgage-related securities, as well as commercial finance assets, which include other asset-backed securities, senior secured corporate loans, equipment leases and notes, trust preferred securities, debt tranches of collateralized debt obligations, and private equity investments mainly issued by financial institutions.
Satellos Bioscience Inc is a Canadian biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation, which Satellos has identified as a root cause of the progressive nature of this disease.